ROCKET PHARMACEUTICALS, INC. RCKT
We are a fully integrated, late-stage biotechnology company focused on the development, manufacturing, and potential commercialization of genetic therapies for rare and often fatal diseases with high unmet medical need. Our innovative multi-platform approach is designed to create best-in-class gene therapy product candidates aimed at correcting the underlying genetic causes of complex inherited cardiomyopathies and related disorders, with the potential to deliver transformative and durable clinical benefits. Our platform is supported by in-house research and development capabilities and current cGMP manufacturing facilities that enable end-to-end control of clinical production, process development, and scale-up for potential commercialization.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M | $105.4M | $57.9M | $53.3M | $14.9M | $6.0M |
| SG&A | $86.5M | $102.0M | $73.3M | $58.8M | $41.8M | $28.9M | $18.2M | $17.9M | $4.9M | $1.6M |
| Total operating expenses | $231.7M | $273.2M | $259.7M | $224.3M | $167.2M | $134.3M | $76.2M | $71.2M | $19.8M | $7.6M |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M | -$134.3M | -$76.2M | -$71.2M | -$19.8M | -$7.6M |
| Interest expense | $1.9M | $1.9M | $1.9M | $1.9M | $3.0M | $7.0M | $6.0M | $6.0M | $0 | $0 |
| Pre-tax income | -$223.1M | -$258.7M | -$245.6M | — | — | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M | -$139.7M | -$77.3M | -$74.5M | -$19.6M | -$7.6M |
| EPS, basic | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 | — | — | — |
| EPS, diluted | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 | -1.89 | -2.88 | -1.11 |
| Shares, diluted (wtd. avg.) | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M | 55.4M | 49.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $77.6M | $163.6M | $57.3M | $141.9M | $234.0M | $298.7M | $186.9M | $112.8M | $18.3M | $9.7M |
| Short-term investments | $111.4M | $208.7M | $317.3M | $215.9M | $156.0M | $185.6M | $118.7M | $94.4M | $0 | $96.7M |
| Total current assets | $192.7M | $378.2M | $378.2M | $364.1M | $392.1M | $487.3M | $307.8M | $209.1M | $19.0M | $128.3M |
| Property, plant and equipment | $28.2M | $36.8M | $39.2M | $29.0M | $22.3M | $19.2M | $29.5M | $2.0M | $985.0K | $1.1M |
| Goodwill | $39.2M | $39.2M | $39.2M | $39.2M | $30.8M | $30.8M | $30.8M | $30.8M | $0 | — |
| Other intangibles | $25.1M | $25.1M | $25.1M | $25.7M | $0 | — | — | — | — | — |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M | $590.8M | $372.1M | $251.3M | $20.1M | $129.6M |
| Accounts payable | $27.3M | $37.8M | $45.8M | $36.7M | $19.6M | $25.5M | $17.4M | $15.4M | $4.5M | $1.6M |
| Total current liabilities | $30.2M | $40.7M | $48.5M | $39.2M | $22.2M | $32.6M | $18.3M | $15.4M | $4.5M | $7.0M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M | $87.3M | $64.8M | $57.3M | $4.6M | $56.5M |
| Retained earnings | -$1.44B | -$1.22B | -$959.4M | -$713.8M | -$491.9M | -$322.8M | -$183.1M | -$105.9M | -$31.4M | -$238.9M |
| Total equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M | $503.5M | $307.3M | $194.0M | $15.5M | $8.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M | -$74.6M | -$64.7M | -$53.8M | -$16.0M | -$5.5M |
| Depreciation and amortisation | $8.9M | $7.2M | $4.9M | $3.9M | $3.2M | $1.1M | $426.0K | $330.0K | $204.0K | $67.0K |
| Stock-based compensation | $37.1M | $43.9M | $39.4M | $31.0M | $29.2M | $18.6M | $13.4M | $13.6M | $1.3M | $274.0K |
| Capital expenditure | $440.0K | $5.9M | $16.4M | $8.4M | $7.6M | $20.6M | $23.3M | $1.5M | $760.0K | $335.0K |
| Investing cash flow | $103.8M | $131.7M | -$98.1M | -$69.3M | $18.9M | -$96.6M | -$39.0M | -$5.3M | -$760.0K | -$335.0K |
| Financing cash flow | $148.0K | $185.7M | $208.4M | $155.3M | $37.7M | $283.0M | $177.8M | $153.5M | $25.4M | $16.0K |
| Buybacks | — | — | — | $47.0K | $0 | $72.0K | $0 | $0 | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-013335.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$7.6M | -$19.6M | -$74.5M | -$77.3M | -$139.7M | -$169.1M | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |